TrialOncotarget2016

A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.

Adrian G Sacher et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.